Skip to content

Comparing Microneedling and Injectable Platelet Rich Fibrin to Hyaluronic Acid In Papilla Reconstruction

Comparative Evaluation of Microneedling With Injectable PRF and Hyaluronic Acid for Papilla Reconstruction: A Randomized Clinical Trial

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07280507
Acronym
(PRF) (HA)
Enrollment
7
Registered
2025-12-12
Start date
2025-11-24
Completion date
2026-09-30
Last updated
2025-12-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Papilla Reconstruction

Keywords

Papilla, Reconstruction, Hyaluronic Acid, Injectable Platelet Rich Fibrin, Microneedling

Brief summary

This randomized split-mouth clinical trial aims to compare the clinical effectiveness of microneedling combined with injectable platelet-rich fibrin (i-PRF) versus hyaluronic acid (HA) gel injection in the reconstruction of Class I interdental papilla loss. The study hypothesizes that MN + i-PRF will yield greater papillary regeneration, offering a minimally invasive, biologically active alternative to traditional surgical approaches for soft-tissue esthetic rehabilitation.

Interventions

Injectable Platelet Rich Fibrin

OTHERHyaluronic Acid (HA)

Filler

Sponsors

King Abdulaziz University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

* Plaque index \<1 * Gingival index \<1 * Class I papillary loss (Nordland and Tarnow classification) * Probing depth ≤4 mm at the test site * Inter-proximal bone crest distance ≤7 mm from the contact point.

Exclusion criteria

* Pregnancy * Lactation * Uncontrolled systemic diseases (e.g., diabetes) * Anticoagulant therapy * Recent radiotherapy * Orthodontic treatment * Midline diastema * High frenum attachment * Class II/III papillary loss.

Design outcomes

Primary

MeasureTime frameDescription
Papillary heightBaseline, 6 weeks, and 12 weeks.from the mucogingival junction to the papilla tip
Papillary width12 weeks

Countries

Saudi Arabia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026